Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MISTIE-III: Minimally Invasive Surgery Plus rt-PA for ICH
NCT01827046Phase 3Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2013
- Primary completion
- Sep 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator in intracerebral hemorrhage (ICH) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Modified Rankin Scale Score 0-3 at 365 days. Started Dec 2013; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT01827046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827046.